Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neisseria gonorrhoeae | 51 | 2024 | 243 | 16.690 |
Why?
|
Gonorrhea | 43 | 2024 | 349 | 15.610 |
Why?
|
Drug Resistance, Bacterial | 33 | 2024 | 1064 | 6.190 |
Why?
|
Anti-Bacterial Agents | 64 | 2024 | 7471 | 5.970 |
Why?
|
Genome, Bacterial | 15 | 2021 | 798 | 3.020 |
Why?
|
Drug Resistance, Microbial | 10 | 2023 | 830 | 2.890 |
Why?
|
Microbial Sensitivity Tests | 32 | 2024 | 1965 | 2.730 |
Why?
|
Ciprofloxacin | 9 | 2024 | 313 | 2.590 |
Why?
|
Azithromycin | 11 | 2023 | 200 | 2.150 |
Why?
|
Doxycycline | 3 | 2024 | 348 | 1.760 |
Why?
|
Homosexuality, Male | 11 | 2024 | 1345 | 1.670 |
Why?
|
Macrolides | 5 | 2022 | 205 | 1.460 |
Why?
|
Respiratory Tract Infections | 4 | 2023 | 1013 | 1.450 |
Why?
|
Disease Outbreaks | 10 | 2024 | 1764 | 1.440 |
Why?
|
Cephalosporin Resistance | 3 | 2020 | 17 | 1.290 |
Why?
|
Molecular Epidemiology | 9 | 2020 | 473 | 1.220 |
Why?
|
Escherichia coli Infections | 4 | 2023 | 524 | 1.080 |
Why?
|
Neisseria meningitidis | 4 | 2022 | 111 | 1.040 |
Why?
|
Basketball | 5 | 2024 | 46 | 1.010 |
Why?
|
Bacterial Proteins | 11 | 2022 | 3861 | 0.990 |
Why?
|
Outpatients | 7 | 2024 | 1607 | 0.980 |
Why?
|
Tetracycline Resistance | 1 | 2024 | 22 | 0.950 |
Why?
|
Staphylococcal Infections | 7 | 2023 | 1412 | 0.920 |
Why?
|
Drug Utilization | 3 | 2019 | 1192 | 0.910 |
Why?
|
Seroepidemiologic Studies | 8 | 2023 | 406 | 0.900 |
Why?
|
Communicable Diseases | 3 | 2024 | 875 | 0.890 |
Why?
|
Seasons | 5 | 2024 | 1526 | 0.890 |
Why?
|
Genomics | 13 | 2023 | 5909 | 0.870 |
Why?
|
Tetracycline | 5 | 2024 | 216 | 0.870 |
Why?
|
Respiratory Syncytial Virus, Human | 2 | 2017 | 149 | 0.860 |
Why?
|
Drug Prescriptions | 4 | 2024 | 1677 | 0.850 |
Why?
|
Ceftriaxone | 5 | 2024 | 175 | 0.810 |
Why?
|
Pharyngitis | 1 | 2024 | 222 | 0.810 |
Why?
|
Genetic Variation | 5 | 2020 | 6610 | 0.800 |
Why?
|
Cephalosporins | 4 | 2020 | 200 | 0.790 |
Why?
|
Streptococcus pyogenes | 1 | 2024 | 293 | 0.770 |
Why?
|
Influenza A Virus, H3N2 Subtype | 2 | 2018 | 85 | 0.750 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 7 | 2024 | 704 | 0.740 |
Why?
|
Phylogeny | 14 | 2023 | 2846 | 0.740 |
Why?
|
Respiratory Syncytial Virus Infections | 2 | 2017 | 365 | 0.730 |
Why?
|
Mumps | 2 | 2020 | 71 | 0.730 |
Why?
|
Drug Resistance, Multiple, Bacterial | 8 | 2020 | 590 | 0.730 |
Why?
|
Influenza Vaccines | 2 | 2018 | 781 | 0.730 |
Why?
|
Virus Shedding | 1 | 2021 | 110 | 0.720 |
Why?
|
Dermatitis | 1 | 2022 | 203 | 0.720 |
Why?
|
Streptococcal Infections | 1 | 2024 | 619 | 0.660 |
Why?
|
Inappropriate Prescribing | 2 | 2021 | 212 | 0.660 |
Why?
|
Disease Transmission, Infectious | 4 | 2021 | 562 | 0.650 |
Why?
|
Longevity | 3 | 2024 | 1077 | 0.640 |
Why?
|
Shiga-Toxigenic Escherichia coli | 2 | 2023 | 26 | 0.630 |
Why?
|
Transportation | 1 | 2020 | 218 | 0.630 |
Why?
|
Post-Exposure Prophylaxis | 3 | 2024 | 113 | 0.620 |
Why?
|
Humans | 120 | 2024 | 768451 | 0.620 |
Why?
|
Mumps Vaccine | 1 | 2018 | 16 | 0.610 |
Why?
|
Bacterial Infections | 5 | 2024 | 1397 | 0.600 |
Why?
|
United States | 30 | 2024 | 73121 | 0.600 |
Why?
|
Genome, Viral | 5 | 2024 | 673 | 0.600 |
Why?
|
Urethritis | 1 | 2017 | 24 | 0.590 |
Why?
|
Public Health | 5 | 2024 | 2693 | 0.590 |
Why?
|
Cefixime | 4 | 2023 | 13 | 0.590 |
Why?
|
DNA-Directed RNA Polymerases | 1 | 2020 | 367 | 0.580 |
Why?
|
Bacteria | 8 | 2022 | 2226 | 0.570 |
Why?
|
Models, Theoretical | 6 | 2024 | 3590 | 0.570 |
Why?
|
Sequence Analysis, DNA | 7 | 2020 | 4780 | 0.560 |
Why?
|
Genotype | 8 | 2021 | 13047 | 0.560 |
Why?
|
High-Throughput Nucleotide Sequencing | 7 | 2018 | 3665 | 0.550 |
Why?
|
Fluoroquinolones | 3 | 2023 | 309 | 0.550 |
Why?
|
Cervix Uteri | 1 | 2020 | 577 | 0.540 |
Why?
|
Cholera | 2 | 2013 | 753 | 0.530 |
Why?
|
RNA, Viral | 2 | 2022 | 2865 | 0.530 |
Why?
|
Evolution, Molecular | 6 | 2020 | 1897 | 0.530 |
Why?
|
Pandemics | 14 | 2024 | 8753 | 0.530 |
Why?
|
Vaccination | 7 | 2022 | 3434 | 0.510 |
Why?
|
Anti-Infective Agents | 2 | 2023 | 987 | 0.500 |
Why?
|
Listeriosis | 1 | 2016 | 147 | 0.480 |
Why?
|
Coronavirus Infections | 7 | 2020 | 3116 | 0.470 |
Why?
|
Pneumonia, Viral | 6 | 2020 | 3240 | 0.450 |
Why?
|
Listeria monocytogenes | 1 | 2016 | 246 | 0.450 |
Why?
|
Staphylococcus aureus | 3 | 2019 | 1461 | 0.450 |
Why?
|
Escherichia coli | 4 | 2022 | 4220 | 0.440 |
Why?
|
Bayes Theorem | 7 | 2023 | 2358 | 0.440 |
Why?
|
Omeprazole | 2 | 2010 | 106 | 0.430 |
Why?
|
Virus Replication | 1 | 2021 | 2459 | 0.430 |
Why?
|
Biological Evolution | 3 | 2021 | 1081 | 0.430 |
Why?
|
Viral Load | 2 | 2022 | 3399 | 0.430 |
Why?
|
Anti-Ulcer Agents | 2 | 2010 | 112 | 0.430 |
Why?
|
Biodiversity | 1 | 2016 | 346 | 0.420 |
Why?
|
Health Status Disparities | 4 | 2022 | 1876 | 0.420 |
Why?
|
Membrane Transport Proteins | 1 | 2018 | 1036 | 0.410 |
Why?
|
Nephritis, Interstitial | 2 | 2010 | 158 | 0.410 |
Why?
|
Antibodies, Viral | 7 | 2024 | 3212 | 0.410 |
Why?
|
Social Class | 1 | 2021 | 2000 | 0.400 |
Why?
|
Models, Biological | 4 | 2020 | 9505 | 0.400 |
Why?
|
Babesiosis | 1 | 2013 | 92 | 0.390 |
Why?
|
Viral Proteins | 3 | 2020 | 1803 | 0.390 |
Why?
|
Peptic Ulcer Hemorrhage | 2 | 2010 | 47 | 0.380 |
Why?
|
Vibrio cholerae O1 | 1 | 2013 | 243 | 0.380 |
Why?
|
Sexually Transmitted Diseases | 3 | 2024 | 666 | 0.370 |
Why?
|
Europe | 5 | 2020 | 3439 | 0.370 |
Why?
|
Anti-Infective Agents, Local | 2 | 2023 | 248 | 0.350 |
Why?
|
Mutation, Missense | 1 | 2020 | 2594 | 0.350 |
Why?
|
Residence Characteristics | 1 | 2020 | 2119 | 0.350 |
Why?
|
Adaptive Immunity | 2 | 2020 | 736 | 0.350 |
Why?
|
New York City | 2 | 2024 | 738 | 0.350 |
Why?
|
Genome-Wide Association Study | 5 | 2023 | 12774 | 0.340 |
Why?
|
Bacterial Vaccines | 3 | 2021 | 400 | 0.340 |
Why?
|
RNA | 1 | 2019 | 2727 | 0.330 |
Why?
|
RNA, Ribosomal, 23S | 2 | 2020 | 54 | 0.320 |
Why?
|
Penicillins | 2 | 2022 | 405 | 0.310 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1228 | 0.310 |
Why?
|
Immunocompromised Host | 1 | 2014 | 867 | 0.310 |
Why?
|
Helicobacter pylori | 1 | 2011 | 382 | 0.300 |
Why?
|
Helicobacter Infections | 1 | 2011 | 392 | 0.300 |
Why?
|
Sensitivity and Specificity | 2 | 2022 | 14728 | 0.300 |
Why?
|
Influenza, Human | 2 | 2018 | 1540 | 0.290 |
Why?
|
Repressor Proteins | 2 | 2018 | 2987 | 0.290 |
Why?
|
Young Adult | 14 | 2024 | 60045 | 0.280 |
Why?
|
Lyme Disease | 1 | 2013 | 631 | 0.270 |
Why?
|
beta-Lactam Resistance | 2 | 2017 | 79 | 0.260 |
Why?
|
Computational Biology | 4 | 2024 | 3546 | 0.260 |
Why?
|
Sequence Homology, Nucleic Acid | 3 | 2004 | 1056 | 0.260 |
Why?
|
Genes, Bacterial | 3 | 2020 | 1076 | 0.260 |
Why?
|
Epistasis, Genetic | 2 | 2018 | 352 | 0.260 |
Why?
|
Linkage Disequilibrium | 3 | 2020 | 1998 | 0.250 |
Why?
|
Antibodies, Bacterial | 1 | 2011 | 1481 | 0.250 |
Why?
|
Male | 29 | 2024 | 364781 | 0.250 |
Why?
|
Demography | 2 | 2021 | 1643 | 0.250 |
Why?
|
Prevalence | 5 | 2024 | 15880 | 0.240 |
Why?
|
Mutation | 11 | 2021 | 30243 | 0.240 |
Why?
|
DNA Transposable Elements | 2 | 2019 | 762 | 0.230 |
Why?
|
DNA Footprinting | 1 | 2004 | 97 | 0.230 |
Why?
|
Recombination, Genetic | 2 | 2020 | 1526 | 0.230 |
Why?
|
Vaccines | 2 | 2024 | 845 | 0.220 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2010 | 2279 | 0.220 |
Why?
|
Gene Expression Regulation, Bacterial | 2 | 2020 | 1139 | 0.210 |
Why?
|
Regulatory Sequences, Nucleic Acid | 2 | 2004 | 792 | 0.210 |
Why?
|
Adult | 19 | 2024 | 223542 | 0.210 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7451 | 0.200 |
Why?
|
DNA Gyrase | 1 | 2023 | 86 | 0.200 |
Why?
|
Chromosome Mapping | 3 | 2014 | 4622 | 0.200 |
Why?
|
DNA, Bacterial | 3 | 2019 | 1474 | 0.200 |
Why?
|
Uncertainty | 2 | 2021 | 758 | 0.200 |
Why?
|
Hexosyltransferases | 1 | 2022 | 58 | 0.200 |
Why?
|
Decision Support Techniques | 1 | 2012 | 2010 | 0.200 |
Why?
|
Aspirin | 2 | 2010 | 3139 | 0.200 |
Why?
|
Sequence Alignment | 2 | 2017 | 2184 | 0.190 |
Why?
|
Binding Sites | 2 | 2020 | 6030 | 0.190 |
Why?
|
Transformation, Bacterial | 2 | 2018 | 79 | 0.190 |
Why?
|
Adaptation, Physiological | 2 | 2018 | 1315 | 0.190 |
Why?
|
Base Sequence | 5 | 2021 | 12428 | 0.190 |
Why?
|
Gene Transfer, Horizontal | 2 | 2020 | 149 | 0.190 |
Why?
|
Convalescence | 1 | 2021 | 109 | 0.180 |
Why?
|
Coronaviridae Infections | 1 | 2020 | 10 | 0.180 |
Why?
|
Haiti | 2 | 2013 | 553 | 0.180 |
Why?
|
Quarantine | 2 | 2020 | 187 | 0.180 |
Why?
|
Streptococcus pneumoniae | 3 | 2020 | 765 | 0.180 |
Why?
|
Prescriptions | 1 | 2023 | 387 | 0.170 |
Why?
|
Mumps virus | 1 | 2020 | 23 | 0.170 |
Why?
|
Cross Reactions | 2 | 2020 | 828 | 0.170 |
Why?
|
England | 2 | 2018 | 533 | 0.170 |
Why?
|
Immunization, Secondary | 1 | 2022 | 371 | 0.170 |
Why?
|
Operon | 1 | 2020 | 372 | 0.170 |
Why?
|
Mass Vaccination | 1 | 2021 | 110 | 0.170 |
Why?
|
Sexual Behavior | 2 | 2019 | 2200 | 0.160 |
Why?
|
Daptomycin | 1 | 2019 | 71 | 0.160 |
Why?
|
Bacterial Typing Techniques | 1 | 2020 | 263 | 0.160 |
Why?
|
Fimbriae Proteins | 2 | 2022 | 133 | 0.160 |
Why?
|
Off-Label Use | 1 | 2021 | 186 | 0.160 |
Why?
|
Sample Size | 1 | 2022 | 851 | 0.160 |
Why?
|
Bile Acids and Salts | 1 | 2021 | 398 | 0.160 |
Why?
|
Serologic Tests | 1 | 2021 | 383 | 0.160 |
Why?
|
Kinetics | 2 | 2023 | 6348 | 0.160 |
Why?
|
Medicare Part C | 1 | 2024 | 332 | 0.150 |
Why?
|
Algorithms | 4 | 2019 | 14158 | 0.150 |
Why?
|
Carbon Dioxide | 1 | 2023 | 1152 | 0.150 |
Why?
|
Antibiotic Prophylaxis | 1 | 2023 | 640 | 0.150 |
Why?
|
Nitrite Reductases | 1 | 2017 | 5 | 0.150 |
Why?
|
Massachusetts | 2 | 2021 | 8908 | 0.150 |
Why?
|
Promoter Regions, Genetic | 2 | 2020 | 5803 | 0.150 |
Why?
|
Selection, Genetic | 2 | 2020 | 877 | 0.150 |
Why?
|
Carrier State | 4 | 2023 | 529 | 0.150 |
Why?
|
Adolescent | 9 | 2024 | 89168 | 0.150 |
Why?
|
Ferrets | 1 | 2018 | 181 | 0.150 |
Why?
|
Propionates | 1 | 2018 | 180 | 0.150 |
Why?
|
Health Priorities | 1 | 2021 | 379 | 0.150 |
Why?
|
Sexual Partners | 2 | 2019 | 806 | 0.150 |
Why?
|
Child | 7 | 2024 | 80863 | 0.150 |
Why?
|
Contact Tracing | 1 | 2020 | 275 | 0.150 |
Why?
|
Aged | 11 | 2024 | 171520 | 0.150 |
Why?
|
Group Processes | 1 | 2019 | 228 | 0.140 |
Why?
|
Quality-Adjusted Life Years | 1 | 2024 | 1734 | 0.140 |
Why?
|
Communicable Disease Control | 1 | 2024 | 857 | 0.140 |
Why?
|
Drosophila | 2 | 2004 | 1514 | 0.140 |
Why?
|
R Factors | 1 | 2017 | 35 | 0.140 |
Why?
|
Insurance | 1 | 2018 | 115 | 0.140 |
Why?
|
Risk Assessment | 1 | 2018 | 24311 | 0.140 |
Why?
|
Middle Aged | 13 | 2024 | 223418 | 0.140 |
Why?
|
Eggs | 1 | 2018 | 182 | 0.140 |
Why?
|
Adaptation, Biological | 1 | 2018 | 147 | 0.140 |
Why?
|
Epitopes, B-Lymphocyte | 1 | 2017 | 85 | 0.140 |
Why?
|
Athletes | 2 | 2022 | 1162 | 0.140 |
Why?
|
Infant | 5 | 2024 | 36497 | 0.140 |
Why?
|
Biosynthetic Pathways | 1 | 2017 | 138 | 0.140 |
Why?
|
Flavivirus | 1 | 2016 | 23 | 0.140 |
Why?
|
Lip | 1 | 2018 | 198 | 0.140 |
Why?
|
Genomic Islands | 1 | 2016 | 52 | 0.130 |
Why?
|
Databases, Genetic | 2 | 2019 | 1750 | 0.130 |
Why?
|
Bacterial Capsules | 1 | 2017 | 246 | 0.130 |
Why?
|
Incidence | 3 | 2024 | 21552 | 0.130 |
Why?
|
Cryoelectron Microscopy | 1 | 2020 | 652 | 0.130 |
Why?
|
Fatigue | 3 | 2013 | 1556 | 0.130 |
Why?
|
beta-Lactamases | 2 | 2017 | 307 | 0.130 |
Why?
|
Molecular Sequence Data | 5 | 2014 | 17647 | 0.130 |
Why?
|
Chikungunya virus | 1 | 2016 | 56 | 0.130 |
Why?
|
Carbapenems | 1 | 2017 | 125 | 0.130 |
Why?
|
DNA, Ribosomal | 1 | 2016 | 301 | 0.130 |
Why?
|
Pharynx | 1 | 2018 | 436 | 0.130 |
Why?
|
Pregnant Women | 1 | 2020 | 576 | 0.130 |
Why?
|
Enterobacteriaceae | 1 | 2017 | 161 | 0.120 |
Why?
|
Communicable Diseases, Emerging | 1 | 2017 | 149 | 0.120 |
Why?
|
Cross-Sectional Studies | 4 | 2024 | 26351 | 0.120 |
Why?
|
Viral Vaccines | 1 | 2020 | 596 | 0.120 |
Why?
|
Codon | 1 | 2017 | 599 | 0.120 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 749 | 0.120 |
Why?
|
Host-Pathogen Interactions | 3 | 2019 | 1465 | 0.120 |
Why?
|
Enterobacteriaceae Infections | 1 | 2017 | 190 | 0.120 |
Why?
|
Retrospective Studies | 8 | 2024 | 81834 | 0.120 |
Why?
|
Computer Simulation | 3 | 2023 | 6278 | 0.110 |
Why?
|
Databases, Protein | 1 | 2016 | 387 | 0.110 |
Why?
|
Cost-Benefit Analysis | 2 | 2024 | 5532 | 0.110 |
Why?
|
Antigens, Viral | 1 | 2018 | 992 | 0.110 |
Why?
|
Caenorhabditis elegans | 1 | 2003 | 1462 | 0.110 |
Why?
|
Population Surveillance | 1 | 2024 | 2601 | 0.110 |
Why?
|
Female | 15 | 2024 | 396943 | 0.110 |
Why?
|
Stomach Ulcer | 2 | 2010 | 122 | 0.110 |
Why?
|
Probability | 1 | 2019 | 2483 | 0.110 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2017 | 828 | 0.110 |
Why?
|
Haplotypes | 1 | 2020 | 2725 | 0.110 |
Why?
|
Fatty Acids | 1 | 2021 | 1818 | 0.110 |
Why?
|
Membrane Proteins | 2 | 2022 | 7895 | 0.110 |
Why?
|
Genetic Markers | 1 | 2019 | 2604 | 0.110 |
Why?
|
Ambulatory Care | 1 | 2024 | 2780 | 0.110 |
Why?
|
Interspersed Repetitive Sequences | 1 | 2013 | 53 | 0.100 |
Why?
|
Gene Frequency | 1 | 2020 | 3615 | 0.100 |
Why?
|
Reference Standards | 1 | 2016 | 1015 | 0.100 |
Why?
|
Nepal | 1 | 2013 | 301 | 0.100 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2013 | 106 | 0.100 |
Why?
|
Zimbabwe | 1 | 2012 | 135 | 0.100 |
Why?
|
Water Purification | 1 | 2012 | 60 | 0.100 |
Why?
|
Age Distribution | 2 | 2023 | 2881 | 0.100 |
Why?
|
Antigens, Bacterial | 1 | 2017 | 1150 | 0.100 |
Why?
|
Bacterial Outer Membrane Proteins | 1 | 2014 | 404 | 0.100 |
Why?
|
Urinalysis | 2 | 2010 | 369 | 0.100 |
Why?
|
Child, Preschool | 3 | 2024 | 42623 | 0.090 |
Why?
|
Health Services Research | 1 | 2018 | 1815 | 0.090 |
Why?
|
Hospitals | 2 | 2023 | 3906 | 0.090 |
Why?
|
Immunity, Herd | 2 | 2021 | 48 | 0.090 |
Why?
|
Reproducibility of Results | 3 | 2019 | 20231 | 0.090 |
Why?
|
MicroRNAs | 2 | 2003 | 3805 | 0.090 |
Why?
|
Models, Genetic | 3 | 2013 | 3442 | 0.090 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2018 | 938 | 0.090 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2014 | 2751 | 0.080 |
Why?
|
Urination Disorders | 1 | 2010 | 238 | 0.080 |
Why?
|
Antigens | 1 | 2014 | 1443 | 0.080 |
Why?
|
Infant, Newborn | 4 | 2022 | 26395 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6537 | 0.080 |
Why?
|
Comorbidity | 1 | 2023 | 10601 | 0.070 |
Why?
|
Gene Expression Profiling | 1 | 2004 | 9507 | 0.070 |
Why?
|
Boston | 2 | 2017 | 9361 | 0.070 |
Why?
|
Epidemics | 1 | 2013 | 517 | 0.070 |
Why?
|
Research Design | 1 | 2023 | 6217 | 0.070 |
Why?
|
Phenotype | 3 | 2021 | 16712 | 0.070 |
Why?
|
Species Specificity | 2 | 2018 | 2422 | 0.070 |
Why?
|
Age Factors | 2 | 2021 | 18478 | 0.070 |
Why?
|
Mycobacterium tuberculosis | 1 | 2018 | 1931 | 0.070 |
Why?
|
Insurance, Health | 1 | 2019 | 2513 | 0.070 |
Why?
|
Animals | 8 | 2020 | 169418 | 0.070 |
Why?
|
Models, Statistical | 1 | 2021 | 5103 | 0.070 |
Why?
|
Diagnosis, Differential | 2 | 2013 | 13026 | 0.070 |
Why?
|
Diarrhea | 1 | 2013 | 1320 | 0.060 |
Why?
|
Cluster Analysis | 1 | 2013 | 2731 | 0.060 |
Why?
|
Clone Cells | 2 | 2021 | 1672 | 0.060 |
Why?
|
Fever | 1 | 2013 | 1622 | 0.060 |
Why?
|
Kidney | 2 | 2010 | 7064 | 0.060 |
Why?
|
Sex Factors | 1 | 2019 | 10647 | 0.060 |
Why?
|
Gene Expression Regulation | 1 | 2003 | 11930 | 0.060 |
Why?
|
Prospective Studies | 3 | 2021 | 54914 | 0.060 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15460 | 0.060 |
Why?
|
Glucocorticoids | 2 | 2010 | 2170 | 0.060 |
Why?
|
Nutrition Surveys | 1 | 2011 | 1734 | 0.060 |
Why?
|
Polyribosomes | 1 | 2003 | 109 | 0.060 |
Why?
|
Consensus Sequence | 1 | 2004 | 363 | 0.060 |
Why?
|
Medical Informatics Computing | 1 | 2003 | 23 | 0.050 |
Why?
|
Erythrocytes | 1 | 2013 | 2422 | 0.050 |
Why?
|
Shiga Toxin | 1 | 2023 | 36 | 0.050 |
Why?
|
Severity of Illness Index | 1 | 2021 | 15965 | 0.050 |
Why?
|
Genes, Regulator | 1 | 2004 | 373 | 0.050 |
Why?
|
Aged, 80 and over | 2 | 2018 | 59680 | 0.050 |
Why?
|
HIV Infections | 2 | 2019 | 17564 | 0.050 |
Why?
|
Amino Acid Sequence | 1 | 2014 | 13452 | 0.050 |
Why?
|
Immunity, Innate | 1 | 2014 | 3080 | 0.050 |
Why?
|
Mupirocin | 1 | 2022 | 55 | 0.050 |
Why?
|
Combinatorial Chemistry Techniques | 1 | 2002 | 136 | 0.050 |
Why?
|
Cross Infection | 2 | 2024 | 1425 | 0.050 |
Why?
|
O Antigens | 1 | 2023 | 196 | 0.050 |
Why?
|
Time Factors | 1 | 2023 | 40271 | 0.050 |
Why?
|
Fimbriae, Bacterial | 1 | 2022 | 138 | 0.050 |
Why?
|
Rwanda | 1 | 2024 | 669 | 0.050 |
Why?
|
Methicillin Resistance | 1 | 2022 | 198 | 0.050 |
Why?
|
Physicians' Offices | 1 | 2021 | 60 | 0.050 |
Why?
|
Kenya | 1 | 2024 | 757 | 0.050 |
Why?
|
Plasmids | 2 | 2016 | 2269 | 0.050 |
Why?
|
Coronaviridae | 1 | 2020 | 13 | 0.050 |
Why?
|
pol Gene Products, Human Immunodeficiency Virus | 1 | 2020 | 41 | 0.050 |
Why?
|
Masks | 1 | 2023 | 215 | 0.040 |
Why?
|
Coronavirus OC43, Human | 1 | 2020 | 18 | 0.040 |
Why?
|
Voluntary Programs | 1 | 2020 | 48 | 0.040 |
Why?
|
Sodium Azide | 1 | 2019 | 24 | 0.040 |
Why?
|
Medicare | 1 | 2018 | 6881 | 0.040 |
Why?
|
Abetalipoproteinemia | 1 | 2019 | 16 | 0.040 |
Why?
|
Victoria | 1 | 2019 | 64 | 0.040 |
Why?
|
Phylogeography | 1 | 2019 | 72 | 0.040 |
Why?
|
Cohort Studies | 2 | 2022 | 41797 | 0.040 |
Why?
|
Topoisomerase Inhibitors | 1 | 2019 | 19 | 0.040 |
Why?
|
United States Department of Veterans Affairs | 1 | 2024 | 937 | 0.040 |
Why?
|
Rhinovirus | 1 | 2020 | 210 | 0.040 |
Why?
|
Uganda | 1 | 2024 | 1350 | 0.040 |
Why?
|
Spiro Compounds | 1 | 2019 | 69 | 0.040 |
Why?
|
Molecular Structure | 1 | 2003 | 1889 | 0.040 |
Why?
|
Drug Utilization Review | 1 | 2020 | 248 | 0.040 |
Why?
|
New York | 1 | 2021 | 882 | 0.040 |
Why?
|
Time | 1 | 2020 | 546 | 0.040 |
Why?
|
Acyl Coenzyme A | 1 | 2018 | 57 | 0.040 |
Why?
|
Barbiturates | 1 | 2019 | 113 | 0.040 |
Why?
|
Oxazolidinones | 1 | 2019 | 98 | 0.040 |
Why?
|
Polymorphism, Genetic | 2 | 2021 | 4249 | 0.040 |
Why?
|
Privacy | 1 | 2020 | 233 | 0.040 |
Why?
|
Penicillin G | 1 | 2017 | 40 | 0.040 |
Why?
|
Socioeconomic Factors | 1 | 2011 | 7863 | 0.040 |
Why?
|
Alcohol Drinking | 1 | 2010 | 4052 | 0.040 |
Why?
|
Alleles | 2 | 2021 | 6890 | 0.040 |
Why?
|
Public Health Practice | 1 | 2020 | 221 | 0.040 |
Why?
|
Neonatal Screening | 1 | 2022 | 618 | 0.040 |
Why?
|
Immune Evasion | 1 | 2021 | 377 | 0.040 |
Why?
|
Isoxazoles | 1 | 2019 | 233 | 0.040 |
Why?
|
Vaccines, Conjugate | 1 | 2018 | 334 | 0.030 |
Why?
|
Smallpox | 1 | 2017 | 43 | 0.030 |
Why?
|
Africa | 1 | 2019 | 726 | 0.030 |
Why?
|
Nasal Cavity | 1 | 2019 | 309 | 0.030 |
Why?
|
Cities | 1 | 2019 | 546 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2022 | 65409 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2018 | 16029 | 0.030 |
Why?
|
Logistic Models | 1 | 2011 | 13324 | 0.030 |
Why?
|
Encephalitis Virus, Japanese | 1 | 2016 | 12 | 0.030 |
Why?
|
Yellow fever virus | 1 | 2016 | 23 | 0.030 |
Why?
|
Isoniazid | 1 | 2018 | 288 | 0.030 |
Why?
|
Glycosylation | 1 | 2019 | 1100 | 0.030 |
Why?
|
Hepatitis A | 1 | 2017 | 127 | 0.030 |
Why?
|
Multilocus Sequence Typing | 1 | 2016 | 102 | 0.030 |
Why?
|
West Nile virus | 1 | 2016 | 77 | 0.030 |
Why?
|
Severe Acute Respiratory Syndrome | 1 | 2017 | 137 | 0.030 |
Why?
|
Molecular Typing | 1 | 2016 | 116 | 0.030 |
Why?
|
Morpholines | 1 | 2019 | 583 | 0.030 |
Why?
|
Insect Vectors | 1 | 2016 | 136 | 0.030 |
Why?
|
Aftercare | 1 | 2021 | 921 | 0.030 |
Why?
|
Chromosomes, Bacterial | 1 | 2016 | 281 | 0.030 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2022 | 861 | 0.030 |
Why?
|
Pneumococcal Vaccines | 1 | 2018 | 414 | 0.030 |
Why?
|
Risk Factors | 2 | 2019 | 74915 | 0.030 |
Why?
|
Monte Carlo Method | 1 | 2020 | 1262 | 0.030 |
Why?
|
Erythromycin | 1 | 2014 | 115 | 0.030 |
Why?
|
Glycoproteins | 1 | 2022 | 2206 | 0.030 |
Why?
|
Dengue Virus | 1 | 2016 | 204 | 0.030 |
Why?
|
Adhesins, Bacterial | 1 | 2014 | 120 | 0.030 |
Why?
|
Infection Control | 1 | 2021 | 985 | 0.030 |
Why?
|
Molecular Sequence Annotation | 1 | 2016 | 526 | 0.030 |
Why?
|
Pneumococcal Infections | 1 | 2018 | 529 | 0.030 |
Why?
|
Minority Groups | 1 | 2021 | 1215 | 0.030 |
Why?
|
Vagina | 1 | 2019 | 845 | 0.030 |
Why?
|
Immunologic Memory | 1 | 2020 | 1375 | 0.030 |
Why?
|
Research | 1 | 2022 | 1984 | 0.030 |
Why?
|
Penicillin-Binding Proteins | 1 | 2014 | 152 | 0.030 |
Why?
|
Triazoles | 1 | 2019 | 905 | 0.030 |
Why?
|
Light | 1 | 2019 | 1357 | 0.030 |
Why?
|
Polysaccharides | 1 | 2019 | 1024 | 0.030 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2004 | 3612 | 0.030 |
Why?
|
World Health Organization | 1 | 2019 | 1328 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2019 | 2204 | 0.030 |
Why?
|
Gene Dosage | 1 | 2016 | 1221 | 0.020 |
Why?
|
China | 1 | 2018 | 2398 | 0.020 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2017 | 424 | 0.020 |
Why?
|
Canada | 1 | 2017 | 2143 | 0.020 |
Why?
|
Point Mutation | 1 | 2016 | 1596 | 0.020 |
Why?
|
Urban Population | 1 | 2019 | 2047 | 0.020 |
Why?
|
Cost of Illness | 1 | 2021 | 1960 | 0.020 |
Why?
|
Veterans | 1 | 2024 | 2671 | 0.020 |
Why?
|
Decision Making | 1 | 2024 | 3961 | 0.020 |
Why?
|
Software | 1 | 2004 | 4463 | 0.020 |
Why?
|
Antitubercular Agents | 1 | 2018 | 1390 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3063 | 0.020 |
Why?
|
Quantitative Trait Loci | 1 | 2018 | 2127 | 0.020 |
Why?
|
Histamine H2 Antagonists | 1 | 2010 | 169 | 0.020 |
Why?
|
Methylprednisolone | 1 | 2010 | 387 | 0.020 |
Why?
|
Genome | 1 | 2016 | 1749 | 0.020 |
Why?
|
Patient Discharge | 1 | 2021 | 3471 | 0.020 |
Why?
|
Treatment Failure | 1 | 2014 | 2656 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 4419 | 0.020 |
Why?
|
Oxygen | 1 | 2019 | 4269 | 0.020 |
Why?
|
Health Policy | 1 | 2020 | 2699 | 0.020 |
Why?
|
Health Promotion | 1 | 2019 | 2215 | 0.020 |
Why?
|
HIV | 1 | 2014 | 1596 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2019 | 3697 | 0.020 |
Why?
|
Health Status | 1 | 2020 | 4096 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 8051 | 0.020 |
Why?
|
Quality Assurance, Health Care | 1 | 2016 | 2179 | 0.020 |
Why?
|
Creatinine | 1 | 2010 | 1915 | 0.010 |
Why?
|
Neurons | 1 | 2003 | 9504 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5367 | 0.010 |
Why?
|
Databases, Factual | 1 | 2020 | 8081 | 0.010 |
Why?
|
Cell Fractionation | 1 | 2003 | 248 | 0.010 |
Why?
|
Macrophages | 1 | 2018 | 5797 | 0.010 |
Why?
|
3' Flanking Region | 1 | 2002 | 14 | 0.010 |
Why?
|
HIV-1 | 1 | 2020 | 6966 | 0.010 |
Why?
|
Hospitalization | 1 | 2023 | 10845 | 0.010 |
Why?
|
Myogenic Regulatory Factors | 1 | 2002 | 102 | 0.010 |
Why?
|
Base Composition | 1 | 2002 | 291 | 0.010 |
Why?
|
Genes, Insect | 1 | 2002 | 265 | 0.010 |
Why?
|
Acute Disease | 1 | 2010 | 7246 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2021 | 39430 | 0.010 |
Why?
|
Mesoderm | 1 | 2002 | 679 | 0.010 |
Why?
|
Conserved Sequence | 1 | 2002 | 1164 | 0.010 |
Why?
|
Biopsy | 1 | 2010 | 6816 | 0.010 |
Why?
|
Ultrasonography | 1 | 2010 | 5995 | 0.010 |
Why?
|
Protein Biosynthesis | 1 | 2003 | 2096 | 0.010 |
Why?
|
Enhancer Elements, Genetic | 1 | 2002 | 1368 | 0.010 |
Why?
|
Neuronal Plasticity | 1 | 2003 | 1448 | 0.010 |
Why?
|
Drosophila melanogaster | 1 | 2002 | 1725 | 0.010 |
Why?
|
Drosophila Proteins | 1 | 2002 | 1712 | 0.010 |
Why?
|
Homeodomain Proteins | 1 | 2002 | 2430 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2003 | 19041 | 0.000 |
Why?
|
Rats | 1 | 2003 | 23839 | 0.000 |
Why?
|
Cerebral Cortex | 1 | 2003 | 5827 | 0.000 |
Why?
|
DNA-Binding Proteins | 1 | 2002 | 9623 | 0.000 |
Why?
|
Transcription Factors | 1 | 2002 | 12174 | 0.000 |
Why?
|
Mice | 1 | 2003 | 82045 | 0.000 |
Why?
|